New Update of Appendix 1 of the Nitrosamines Guideline - EMA/42261/2025/Rev. 11
- Home
- regulatory updates
- New Update of Appendix 1 of the Nitrosamines Guideline - EMA/42261/2025/Rev. 11
New Update of Appendix 1 of the Nitrosamines Guideline - EMA/42261/2025/Rev. 11
Regulatory Affairs Pharma & Biotech Toxicology
Thursday, 04 December 2025
Pablo Palomar, Senior Toxicology Officer at QbD Group
Share
\
\
X (Twitter) 
\
\
LinkedIn 
\
\
WhatsApp 
\
\
Copy link 
\
\
Mail
On 01/12/2025, the European Medicines Agency (EMA) released an update to Appendix 1 (EMA/42261/2025/Rev. 11) of the Nitrosamines Guideline. This appendix lists nitrosamines for which an established Acceptable Intake (AI) is available.
Play
New Update of Appendix 1 of the Nitrosamines Guideline | QbD Group
AI-generated audio
1:33
What's new?
This update introduces the Acceptable Intake (AI) values for new nitrosamine drug substance–related impurities (NDSRIs) associated with the manufacturing processes of several active substances (levodropropizine, cytisine, lumefantrine, mifepristone, tapentadol, and selumetinib). In addition, the acceptable intake for the nitrosamine arising from the use of the fragrance ingredient methyl N-methylanthranilate has also been established.
What does this mean to you?
If you market medicines containing any of the substances listed above, you should verify if the potential presence of these new NDSRIs has already been assessed. If not, it is important to promptly update your NRA to account for these risks, particularly for methyl N-methylanthranilate, mifepristone, and tapentadol, which may lead to nitrosamines classified as CPCA category 1 or 2. Some regulatory agencies may request confirmatory testing even when no direct risk of formation has been identified.
If you have already assessed these NDSRIs and identified a risk, review whether the AI values used in your previous evaluation have changed, as updated limits may impact the conclusions of past confirmatory analyses.
Worried about Nitrosamine compliance?
Our experts provide end-to-end assessments, AI calculations, and tailored NRA reports to keep your products safe and compliant.
Discover more expert content
Previous
Regulatory Affairs
2 Jun 2025
Nitrosamines Update EMA/409815/2020 Rev.22
What is new?
Regulatory Affairs
14 May 2024
Latest Update on Appendix 1 of the Nitrosamine Guidelines
On 01/05/2024, the European Medicines Agency (EMA) rolled out an update to Appendix 1...
Regulatory Affairs
27 Jan 2025
New revision to EMA Guidance documents released
Both documents, Guidance on the procedural aspects for the consultation to the European Medicines...
Regulatory Affairs
23 Apr 2024
New EMA Guideline on Environmental Risk Assessment for Human Medicinal Products
New guideline from the European Medicines Agency (EMA) on the Environmental Risk Assessment of...
Regulatory Affairs
9 Jul 2024
New Update of Appendix 1 of the Nitrosamines Guideline
What’s new? In this update, the Acceptable Intake (AI) values for nitrosamines related to the use...
Regulatory Affairs
2 Jun 2025
Nitrosamines Update EMA/409815/2020 Rev.22
What is new?
Regulatory Affairs
14 May 2024
Latest Update on Appendix 1 of the Nitrosamine Guidelines
On 01/05/2024, the European Medicines Agency (EMA) rolled out an update to Appendix 1...
Regulatory Affairs
27 Jan 2025
New revision to EMA Guidance documents released
Both documents, Guidance on the procedural aspects for the consultation to the European Medicines...
Regulatory Affairs
23 Apr 2024
New EMA Guideline on Environmental Risk Assessment for Human Medicinal Products
New guideline from the European Medicines Agency (EMA) on the Environmental Risk Assessment of...
Regulatory Affairs
9 Jul 2024
New Update of Appendix 1 of the Nitrosamines Guideline
What’s new? In this update, the Acceptable Intake (AI) values for nitrosamines related to the use...
Regulatory Affairs
2 Jun 2025
Nitrosamines Update EMA/409815/2020 Rev.22
What is new?
Regulatory Affairs
14 May 2024
Latest Update on Appendix 1 of the Nitrosamine Guidelines
On 01/05/2024, the European Medicines Agency (EMA) rolled out an update to Appendix 1...
Next
- 1
- 2
- 3
Stay ahead in life sciences
Keeping up with the fast-paced life sciences industry doesn’t have to be overwhelming.
Our newsletter delivers the latest insights, industry updates, and expert content directly to your inbox, helping you stay informed and make smarter decisions.
Twitter Widget Iframe